Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022
October 24, 2022
Beyond Air® Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast
October 20, 2022
Beyond Air® Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit® GO at the CHEST Annual Meeting 2022
October 17, 2022
Beyond Cancer™ to Present Pre-Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2022 SITC Annual Meeting
October 5, 2022
Beyond Air® Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis
October 3, 2022
Beyond Air® To Participate in Three Upcoming Investor Conferences
September 16, 2022
Beyond Air® Affiliate Beyond Cancer™ Doses Initial Patient in First-in-Human Phase 1 Study of Ultra-High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov)
August 23, 2022
Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2023
August 11, 2022
Beyond Air® Schedules First Fiscal Quarter 2023 Financial Results Conference Call and Webcast
July 27, 2022
Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022
June 28, 2022

Sign up for updates from Beyond Air, Inc.

Unsubscribe from all email communications. Unsubscribe